Global Oncogene Inhibitors Market – Industry Trends and Forecast to 2029

  • Pharmaceutical
  • Upcoming Report
  • Mar 2022
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60
  • Pharmaceutical
  • Upcoming Report
  • Mar 2022
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60

Global Oncogene Inhibitors Market, By Genes (EGFR, HER, BRCA, Others), Indication (Breast Cancer, Ovarian Cancer, Lung Cancer, Pancreas Cancer, Others), Treatment (Platinum-based Chemotherapy, PARP Inhibitors, Anti-HER Antibodies, EFGR Inhibitors, Others), Route of Administration (Oral, Parenteral), End Users (Hospitals, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Others) - Industry Trends and Forecast to 2029.

Oncogene Inhibitors Market

Market Analysis and Insights

Development of various therapeutics associated with cancer is a daunting task as human genome consists of variety of genes whose function has yet to be determined. Oncogenomics refers to a field that involves screening of genes involved in cancer development. Oncogenes inhibitors are defined as the class of drugs that act on the oncogenes such HER, EFGR or BRCA.

  • Drugs both inhibit the action of mutant genes or antagonist the effect, and prevent them from uncontrollable growth in oncogenes. Data Bridge Market Research analyses that the oncogene inhibitors market is estimated to grow at a 7.70% during the forecast period of 2022 to 2029.

Oncogene Inhibitors Market Dynamics


  • Increase In The Prevalence Of Cancer

The increase in the prevalence of cancer and rise in incidence of various cancer conditions across the globe acts as one of the major factor driving the growth of oncogene inhibitors market.

  • Rise in Demand for Targeted Treatment

In targeted treatment used for cancer, drugs work by targeting the specific genes or proteins that are present in the cancerous cells. Targeted therapy is an emerging field of cancer research, and researchers that accelerate the market growth.

  • Increase In Mergers and Acquisitions

The increase in the number of mergers and acquisitions among manufacturers and research organizations to provide efficient medical care to patients and generate significant revenues by their sales options results in the expansion of the market.

  • Financial support to the researchers for developing novel intervention

Various public and private organizations are increasing their investments in developing novel interventions and treatments that enhance the oncogene inhibitors market.

Additionally, increase in demand for effective therapies, development in technology, surge in healthcare expenditure, and large patient base and superior technology positively affect the oncogene inhibitors market.


Furthermore, advancement in the diagnostic test for oncogenes to help patient in early detection extends profitable opportunities to the market players in the forecast period of 2022 to 2029. Also, orphan drug designation from the regulatory authority that motivates the pharma or biotech companies to invest further will escalate the growth of oncogene inhibitors market.


On the other hand, high cost associated with the inhibitors and limited availability are expected to obstruct the market growth. The long-time approvals are projected to challenge the oncogene inhibitors market in the forecast period of 2022-2029.

.This oncogene inhibitors market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on oncogene inhibitors market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Patient Epidemiology Analysis

Approximately, 19,292,789 new cancer cases were diagnosed throughout the world, according to the Globocan 2020 fact sheet. The global burden of cancers could reach the value of 27.5 million new cancer cases by 2040, according to estimates from the International Agency for Research on Cancer (IARC).

The oncogene inhibitors market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

COVID-19 Impact on Oncogene Inhibitors Market

A decline was witnessed in the diagnoses of cancer globally including, colorectal, lung, breast, esophageal pancreatic and gastric cancers. Centers for Disease Control and Prevention (CDC) along with numerous medical professional organizations recommended that cancer screening and other health prevention services to be postponed to secure the hospital infrastructure for the treatment of COVID-19 patients. The situation in this field is expected to gradually improve.

Global Oncogene Inhibitors Market Scope

The oncogene inhibitors market is segmented on the basis of genes, indication, treatment, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.


  • EGFR
  • HER
  • BRCA
  • Others

On the basis of genes, the Oncogene Inhibitors Market is segmented into EGFR, HER, BRCA and others.


  • Breast Cancer
  • Ovarian Cancer
  • Lung Cancer
  • Pancreas Cancer
  • Others

On the basis of indication, the oncogene inhibitors market is segmented into breast cancer, ovarian cancer, lung cancer, pancreas cancer and others.


  • Platinum-Based Chemotherapy
  • PARP Inhibitors
  • Anti-HER Antibodies
  • EFGR Inhibitors
  • Others

The treatment segment for oncogene inhibitors market includes platinum-based chemotherapy, PARP inhibitors, Anti-HER antibodies, EFGR inhibitors and others.

Route of Administration

  • Oral
  • Parenteral

Route of administration segment of oncogene inhibitors market is segmented into oral and parenteral.


  • Hospitals
  • Specialty Clinics
  • Others

On the basis of end-users, the oncogene inhibitors market is segmented into hospitals, specialty clinics and others.

Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Others

On the basis of distribution channel, oncogene inhibitors market has also been segmented into hospital pharmacy, retail pharmacy and others.

Pipeline Analysis

HER-2 is expressed at high levels on the surface of some cancer cells. Various targeted therapies are directed against HER-2 which is approved to treat certain breast and stomach cancers. AstraZeneca, Merck Sharp & Dohme Corp.. , Pfizer Inc, and CELGENE CORPORATION, among others are some of the manufacturers involved with the development of drugs associated with cancer.

Regulatory Framework: Oncogene Inhibitors Market

US FDA approved Trodelvy (sacituzumab govitecan-hziy) for treating adult patients suffering with triple-negative breast cancer. Trodelvy refers to a Trop-2-directed antibody and topoisomerase inhibitor drug conjugate in April 2020.

Oncogene Inhibitors Market Regional Analysis/Insights

The oncogene inhibitors market is analysed and market size insights and trends are provided by country, genes, indication, treatment, route of administration, end-users and distribution channel as referenced above.

The countries covered in the oncogene inhibitors market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the oncogene inhibitors market due to the increased adoption of cancer therapy and the growing burden of cancers within the region.

Asia-Pacific is expected to witness high growth during the forecast period of 2022 to 2029 because of the surge in research and development activities in the region.

The country section of the report also provides individual market impacting factors and changes in regulations in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Competitive Landscape and Oncogene Inhibitors Market Share Analysis

The oncogene inhibitors market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to oncogene inhibitors market.

Some of the major players operating in the oncogene inhibitors market are AstraZeneca, Merck Sharp & Dohme Corp.., Pfizer Inc, CELGENE CORPORATION, AKRON, Inc., Novartis AG, Galen Limited., Pacira BioSciences, Inc, Johnson & Johnson Services, Inc, Fresenius Kabi AG, Spectrum Pharmaceuticals, Inc., Takeda Pharmaceutical Company Limited., Teva Pharmaceutical Industries Ltd, Cipla Inc, Sun Pharmaceutical Industries Ltd, Shanghai Fosun Pharmaceutical(Group)Co., Ltd, Ingenus and others.

Why Choose Us

Frequently Asked Questions